Clinical Edge Journal Scan

Low extent and incidence of radiographic spinal damage in PsA vs spondyloarthritis


 

Key clinical point: The occurrence of radiographic spinal damage was overall low among patients with psoriatic arthritis (PsA) and spondyloarthritis; however, severe spinal damage and the extent of syndesmophytes led spinal damage were more observed in spondyloarthritis vs PsA.

Major finding: Proportion of patients with PsA vs spondyloarthritis experiencing spinal damage was comparable (10.6% vs 7.9%; P = .320). However, patients with spondyloarthritis and spinal damage vs PsA had higher modified Stoke Ankylosing Spondylitis Spine Scores, indicating severe spinal damage ( P < .05). Syndesmophytes were significantly higher in the total spine of patients with spondyloarthritis vs PsA ( P < .05).

Study details: This study evaluated patients with PsA (n = 312) and spondyloarthritis (n = 213) who had undergone radiographic imaging assessment in the Belgian Epidemiological Psoriatic Arthritis Study (BEPAS) and observational Ghent and Belgian Inflammatory Arthritis and Spondylitis (Be-GIANT) study, respectively.

Disclosures: The BEPAS and Be-GIANT studies were funded by Merck Sharp Dohme Belgium and AbbVie, respectively. Several authors reported ties with various companies, including AbbVie or Merck Sharp Dohme.

Source: de Hooge M et al. Extent of axial damage in psoriatic arthritis and spondyloarthritis: Comparative data from the BEPAS and (Be-)GIANT multicentre cohorts. RMD Open. 2023;9(2):e002994 (May 3). Doi: 10.1136/rmdopen-2023-002994

Recommended Reading

Study identifies risk factors associated with PsA occurrence in patients with psoriasis
Psoriatic Arthritis ICYMI
Commentary: PsA development risks, and a new index, May 2023
Psoriatic Arthritis ICYMI
Secukinumab improves treatment outcomes and inhibits structural damage in PsA
Psoriatic Arthritis ICYMI
Enthesitis resolution similar with secukinumab and adalimumab in PsA
Psoriatic Arthritis ICYMI
Sonographic enthesitis associated with sonographic synovitis and tenosynovitis in PsA
Psoriatic Arthritis ICYMI
Upadacitinib safe and effective in PsA patients with axial involvement
Psoriatic Arthritis ICYMI
Entheseal fibrocartilage abnormalities: A potential imaging biomarker of PsA
Psoriatic Arthritis ICYMI
Concomitant methotrexate has no effect on ustekinumab immunogenicity in PsA
Psoriatic Arthritis ICYMI
Pretreatment systemic inflammatory markers may guide therapeutic approach in PsA
Psoriatic Arthritis ICYMI
Interleukin-17A inhibitor secukinumab safe and effective in oligoarticular PsA
Psoriatic Arthritis ICYMI